Le Lézard
Classified in: Health
Subjects: CCA, FVT

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024


Conference Call and Webcast at 8:30AM Eastern Time

NEW YORK, March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 26, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth-quarter and full year 2023 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

SOURCE Lucid Diagnostics


These press releases may also interest you

at 14:10
Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib...

at 12:25
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...

at 11:30
The Aesthetic Foundation, formerly known as the Aesthetic Surgery Education and Research Foundation (ASERF), proudly announces the election of Dr. Onelio Garcia Jr. "Oni", as its new President. Dr. Garcia's appointment heralds an exciting chapter for...

at 11:03
The Aesthetic Society proudly announces the appointment of Dr. Kiya Movassaghi, a board-certified plastic surgeon from Eugene, OR, as the President of The Aesthetic Society. Dr. Movassaghi's leadership will focus on strategically fortifying The...

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:00
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...



News published on and distributed by: